Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non...
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
About this item
Full title
Author / Creator
Chmielecki, Juliann , Mok, Tony , Wu, Yi-Long , Han, Ji-Youn , Ahn, Myung-Ju , Ramalingam, Suresh S. , John, Thomas , Okamoto, Isamu , Yang, James Chih-Hsin , Shepherd, Frances A. , Bulusu, Krishna C. , Laus, Gianluca , Collins, Barbara , Barrett, J. Carl , Hartmaier, Ryan J. and Papadimitrakopoulou, Vassiliki
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and
EGFR
T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with
EGFR
T790M advanced non-small cell lung cancer (NSC...
Alternative Titles
Full title
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_97023c9e42e0450eab3688b9d4689761
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_97023c9e42e0450eab3688b9d4689761
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-023-35962-x
